Drug

Paclitaxel protein-bound

In clinical development

Emerging researchLate-stage developmentSteady momentum

Also known as Abraxane, Paclitaxel protein-bound particles for injection suspension, Paclitaxel, albumin-bound (human), paclitaxel protein-bound particles+9 more

Abraxane, Paclitaxel protein-bound particles for injection suspension, Paclitaxel, albumin-bound (human), paclitaxel protein-bound particles, Albumin bound paclitaxel, NAB-PACLITAXEL COMPONENT PACLITAXEL, Nab paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticulate paclitaxel, Paclitaxel, nab-Palitaxel, nab-paclitaxel, nabpaclitaxel.

RxNorm486610

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).

Clinical trial2026-07-30Results expected Q3 2033 · ClinicalTrials.gov

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

Clinical trial2026-07-24Results expected Q2 2027 · ClinicalTrials.gov

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Clinical trial2026-07-20Results expected Q2 2030 · ClinicalTrials.gov

A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator's Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Clinical trial2026-07-15Results expected Q1 2028 · ClinicalTrials.gov

Efficacy and Safety of Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer：A Single-arm, Open-label, Phase II Clinical Study

Clinical trial2026-07-15Primary completion · ClinicalTrials.gov

Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

Clinical trial2026-07-10Results expected Q1 2029 · ClinicalTrials.gov

A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)

Clinical trial2026-07-06Results posted · ClinicalTrials.gov

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Clinical trial2026-07-02Results expected Q4 2027 · ClinicalTrials.gov

The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.

Research2024-02-03Nature communications

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.

Research2021-02-18Clinical cancer research : an official journal of the American Association for Cancer Research

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Research2018-10-20The New England journal of medicine

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.

Research2017-07-12The oncologist

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Paclitaxel protein-bound

Aliases & brands

AbraxanePaclitaxel protein-bound particles for injection suspensionPaclitaxel, albumin-bound (human)paclitaxel protein-bound particlesAlbumin bound paclitaxelNAB-PACLITAXEL COMPONENT PACLITAXELNab paclitaxelNanoparticle Albumin-bound PaclitaxelNanoparticulate paclitaxelPaclitaxelnab-Palitaxelnab-paclitaxelnabpaclitaxel

RxNorm CUI

486610

Clinical trials

197 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

197

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 197

Phase 130Phase 1 / 243Phase 293Phase 2 / 31Phase 327Phase 41Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)

CompletedPH IVCelgenen=1432017

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

RecruitingPH IIINational Cancer Institute (NCI)n=3042035

RecruitingPH IIIKey trialMerck Sharp & Dohme LLCn=1,0002033

RecruitingPH IIIMerck Sharp & Dohme LLCn=8512031

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

RecruitingPH IIISWOG Cancer Research Networkn=942030

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)

CompletedPH IIIIncyte Corporationn=5832026

A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

CompletedPH IIBristol-Myers Squibbn=4682026

A Phase Ib, Open-label, Multicenter Dose-expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors

CompletedPH IGenentech, Inc.n=1022026

An Open-label Phase II Trial Evaluating the Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in Early-stage Triple-negative Breast Cancer（NeoSACT）

CompletedPH IIGuangdong Provincial People's Hospitaln=292026

A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

CompletedPH IIIMerck Sharp & Dohme LLCn=7392026

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

CompletedPH I/IIDragonfly Therapeuticsn=2702025

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20172024

Most influential

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

The New England journal of medicine · 2018 · 3,067 cites

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2021 · 68 cites

The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.

Nature communications · 2024 · 61 cites

The oncologist · 2017 · 16 cites

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Triple Negative Breast Neoplasms2

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Paclitaxel

Studied across the same disease area as Paclitaxel protein-bound in the shared literature.

1 shared disease2 shared papers

Atezolizumab

Studied across the same disease area as Paclitaxel protein-bound in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
Europe PMC — research literature
ClinicalTrials.gov — clinical trials